Nonalcoholic Fatty Liver Disease Activity Score

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.

In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA finish line.

WASHINGTON — Children who reside in low-resource neighborhoods may be at increased risk for non-alcoholic fatty liver disease, according to study results presented at The Liver Meeting.

Vibration-controlled transient elastography and fibrosis-4 index are effective alternatives to liver biopsy when evaluating risk for liver-related events in patients with nonalcoholic fatty liver disease, according to study results.

To streamline and validate diagnosis of and clinical trials in non-alcoholic steatohepatitis, one group is on a mission to determine the best non-invasive tests for all physicians to use, according to a presentation.

Terns Pharmaceuticals announced positive top-line results from a phase 1 clinical trial of TERN-501, a thyroid hormone receptor beta agonist for the treatment of nonalcoholic steatohepatitis, according to a press release.

Severe nonalcoholic fatty liver disease may be correlated with Autophagy Related Gene 7 loss-of-function variants, which may impair hepatocellular ballooning and inflammation.

In an exclusive video with Healio Gastroenterology, Eric Lawitz, MD, from the Texas Liver Institute, The University of Texas Health, San Antonio, spoke about the NAVIGATE trial in nonalcoholic steatohepatitis-related cirrhosis.

The AGA Institute Clinical Practice Updates Committee and the Governing Board published evidence-based intervention advice for lifestyle modifications for treating nonalcoholic fatty liver disease in Gastroenterology.

Poxel announced additional positive phase 2a results and plans for a phase 2b trial of PXL770, an oral direct adenosine monophosphate-activated protein kinase activator intended for nonalcoholic steatohepatitis.